Stock RPHM RENEO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Reneo Pharmaceuticals, Inc.

Equities

RPHM

US75974E1038

Real-time Estimate Cboe BZX
Other stock markets
 11:33:35 2024-05-01 am EDT 		5-day change 1st Jan Change
1.69 USD +1.20% Intraday chart for Reneo Pharmaceuticals, Inc. +1.49% +6.56%
Mar. 28 Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 25 North American Morning Briefing : Tech in Focus on -2- DJ

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Tech in Focus on -2-
DJ
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. for $60 million.
CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Reneo Pharmaceuticals, Inc. announces an Equity Buyback for 576,443 shares, for $4.4 million.
CI
Reneo Pharmaceuticals, Inc. authorizes a Buyback Plan.
CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
RENEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Reneo Pharmaceuticals, Inc. Achieves Target Enrollment in the Pivotal Stride Study of Mavodelpar in Primary Mitochondrial Myopathies
CI
Reneo Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Mavodelpar in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
CI
RENEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
RENEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Reneo Pharmaceuticals, Inc. Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study
CI
Reneo Pharmaceuticals, Inc. to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPHM Stock
  4. News Reneo Pharmaceuticals, Inc.
  5. Highlights